Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
November 01 2016 - 4:30PM
Presentation and Webcast on Tuesday, November 8,
2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company
focused on developing and commercializing oral therapies for the
treatment of patients with elevated low density lipoprotein
cholesterol (LDL-C), today announced that president and chief
executive officer, Tim M. Mayleben, will present at the Credit
Suisse 25th Annual Healthcare Conference in Scottsdale, AZ on
Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m.
Eastern Time.
A live, listen-only webcast of the presentation can
be accessed on the investor relations section of the Esperion
website at www.esperion.com. A webcast replay of the
presentation will be archived on the Company's website for 90 days
following the event.
About Bempedoic Acid
Bempedoic acid is a first-in-class ACL inhibitor
that reduces cholesterol biosynthesis and lowers elevated levels of
LDL-C by up-regulating the LDL receptor, but with reduced potential
for muscle-related side effects. Phase 1 and 2 studies conducted
previously in more than 800 patients treated with bempedoic acid
have produced clinically relevant LDL-C lowering results of up to
30 percent as monotherapy, approximately 50 percent in combination
with ezetimibe, and an incremental 20 to 22 percent when added to
stable statin therapy.
Esperion’s Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more
than 20 percent of the population, have elevated LDL-C; an
additional 73 million people in Europe and 30 million people in
Japan also live with elevated LDL-C. Esperion’s mission is to
provide patients and physicians with a new oral therapy to
significantly reduce elevated levels of LDL-C in patients
inadequately treated with current lipid-modifying therapies.
Esperion-discovered and developed, bempedoic acid is an oral LDL-C
lowering therapy in Phase 3 development. The Company plans to
develop bempedoic acid as a monotherapy as well as a fixed dose
combination (FDC) with ezetimibe, with a particular focus on
patients inadequately treated with current lipid-modifying
therapies. It is estimated that approximately 5-20 percent of
patients who are prescribed statins are only able to tolerate less
than the lowest approved daily starting dose of their statin
(“statin intolerant”).
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a
pharmaceutical company focused on developing and commercializing
oral therapies for the treatment of patients with elevated LDL-C.
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the team at Esperion is
committed to developing new LDL-C lowering therapies that will make
a substantial impact on reducing global cardiovascular disease; the
leading cause of death around the world. Bempedoic acid, the
Company’s lead product candidate, significantly reduces elevated
LDL-C levels in patients with hypercholesterolemia, including
patients inadequately treated with current lipid-modifying
therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Media Contact:
Audrey Gross
W2O Group
212.301.7214
agross@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024